FLT3 and acute myeloid leukemia: These 29 patients did not differ significantly from the other patients with regard to cause of AML (secondary versus de novo), AML cell differentiation (FAB classification, CD34 expression), karyotype, FLT3-ITD, NPM1 mutations or survival of the younger patients receiving intensive therapy (Figure 3B).